FDA approves Camzyos for adolescents with symptomatic obstructive hypertrophic cardiomyopathy

Reports

3

Domains carrying it

3

First reported

30 September 2026

Latest report

1 October 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 30 September 2026FDA approves Camzyos for adolescents with symptomatic obstructive hypertrophic cardiomyopathycontemporarypediatrics.com
2. 1 October 2026CAMZYOS is the only FDA-approved therapy for the treatment of oHCM in a pediatric populationnews.bms.com
3. 1 October 2026FDA expands Bristol Myers Squibb's Camzyos into pediatric obstructive hypertrophic cardiomyopathyallsci.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• FDA Approves Mavacamten for Pediatric Patients With Obstructive HCM3 reports · 3 domains · 2 October 2026
• FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage ...4 reports · 4 domains · 1 September 2026
• Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)15 reports · 14 domains · 10 October 2026
• FDA Approves First Treatment for MCT8 Deficiency3 reports · 3 domains · 30 September 2026
• U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for ...2 reports · 2 domains · 20 August 2026
• Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier ...2 reports · 2 domains · 1 September 2026

◆ Share

◆ Evidence

3 reports · 3 domains

• FDA expands Bristol Myers Squibb's Camzyos into pediatric obstructive hypertrophic cardiomyopathyallsci.com · 1 October 2026
• CAMZYOS is the only FDA-approved therapy for the treatment of oHCM in a pediatric populationnews.bms.com · 1 October 2026
• FDA approves Camzyos for adolescents with symptomatic obstructive hypertrophic cardiomyopathycontemporarypediatrics.com · 30 September 2026